Live Attenuated Influenza Vaccine: Is Past Performance a Guarantee of Future Results?

Ravi Jhaveri*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Live attenuated influenza vaccine (LAIV) has had a tumultuous recent history that can be difficult for many to follow and understand. Prior to 2013, LAIV had a record of accomplishment of providing equal or superior protection against influenza in children. Since 2013, concerns about the lack of protection with LAIV against pandemic H1N1 strains led to the withdrawal of any recommendation for use in the US by the Advisory Committee on Immunization Practices (ACIP). After some significant changes to the content, evaluation and production of LAIV, it has been be recommended again for use in the US in 2018-19. This commentary reviews the origin of LAIV, the events and circumstances that led to the withdrawal of any recommendation for LAIV use by the ACIP, the merits, shortcomings and repercussions of that decision and finally offers some thoughts about the future of LAIV.

Original languageEnglish (US)
Pages (from-to)1246-1254
Number of pages9
JournalClinical Therapeutics
Volume40
Issue number8
DOIs
StatePublished - Aug 1 2018

Keywords

  • influenza
  • live attenuated vaccine
  • recommendations
  • United States

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Live Attenuated Influenza Vaccine: Is Past Performance a Guarantee of Future Results?'. Together they form a unique fingerprint.

Cite this